Compare · CBUS vs NITO
CBUS vs NITO
Side-by-side comparison of Cibus Inc. (CBUS) and N2OFF Inc. (NITO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBUS and NITO operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- CBUS carries a market cap of $106.9M.
- Over the past year, CBUS is down 9.7% and NITO is down 86.9% - CBUS leads by 77.1 points.
- CBUS has hit the wire 14 times in the past 4 weeks while NITO has been quiet.
- CBUS has more recent analyst coverage (4 ratings vs 0 for NITO).
PerformanceCBUS+1.83%NITO-86.87%
2025-09-15+0.00%2026-06-04
- Company
- Cibus Inc.
- N2OFF Inc.
- Price
- $1.39+0.72%
- $1.25+32.98%
- Market cap
- $106.9M
- -
- 1M return
- -9.45%
- -15.54%
- 1Y return
- -9.74%
- -86.87%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 14
- 0
- Recent ratings
- 4
- 0
Latest CBUS
- SEC Form 4 filed by Director Finn Mark Terrence
- SEC Form 4 filed by Director Moretti August J
- SEC Form 4 filed by Director Riggs Rory B
- Director Prante Gerhard was granted 64,748 shares, increasing direct ownership by 161% to 104,945 units (SEC Form 4)
- Director Lehmann Jean-Pierre Jules was granted 64,748 shares, increasing direct ownership by 9% to 763,904 units (SEC Form 4)
- SEC Form 4 filed by Director Box Kimberly Ann
- SEC Form 4 filed by Director Wichner Craig
- Director Urban Thomas was granted 64,748 shares (SEC Form 4)
- SEC Form EFFECT filed by Cibus Inc.
- SEC Form 424B3 filed by Cibus Inc.
Latest NITO
- SEC Form PRE 14A filed by N2OFF Inc.
- N2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- N2OFF Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure
- N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company
- MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases
- Chief Executive Officer Palach David was granted 100,000 units of Restricted Shares of Common Stock (SEC Form 4)
- Controller Zakai Shlomo was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)
- Director Weiss Amitay was granted 116,286 units of Restricted Shares of Common Stock (SEC Form 4)
- Chief Financial Officer Barda Lital was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)
- In Spaceflight Conditions: N2OFF's MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions